世界のフォンウィルブランド病(VWD)治療薬市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV05054)
◆英語タイトル:Global Von Willebrand Disease (VWD) Therapeutics Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV05054
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2023年版があります。お問い合わせください。)
◆ページ数:92
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥538,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥807,300見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,076,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートはフォンウィルブランド病(VWD)治療薬の世界市場について調査・分析した資料です。種類別(デスモプレシン、血栓安定化薬、線維素溶解阻害剤、補充療法、その他)の市場規模、用途別(病院薬局、小売薬局、オンライン薬局)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別フォンウィルブランド病(VWD)治療薬の競争状況、市場シェア
・世界のフォンウィルブランド病(VWD)治療薬市場:種類別市場規模 2015年-2020年(デスモプレシン、血栓安定化薬、線維素溶解阻害剤、補充療法、その他)
・世界のフォンウィルブランド病(VWD)治療薬市場:種類別市場規模予測 2021年-2026年(デスモプレシン、血栓安定化薬、線維素溶解阻害剤、補充療法、その他)
・世界のフォンウィルブランド病(VWD)治療薬市場:用途別市場規模 2015年-2020年(病院薬局、小売薬局、オンライン薬局)
・世界のフォンウィルブランド病(VWD)治療薬市場:用途別市場規模予測 2021年-2026年(病院薬局、小売薬局、オンライン薬局)
・北米のフォンウィルブランド病(VWD)治療薬市場分析:米国、カナダ
・ヨーロッパのフォンウィルブランド病(VWD)治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアのフォンウィルブランド病(VWD)治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米のフォンウィルブランド病(VWD)治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカのフォンウィルブランド病(VWD)治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Apollo Therapeutics、Apotex、Bayer、Bio Products Laboratory、CSL、Ferring Pharmaceuticals、Glenmark Pharmaceuticals、Grifols、Octapharma、Takeda
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Von Willebrand Disease is an inherited bleeding disorder that is caused by deficiency or dysfunction of Von Willebrand Factor (VWF). VWF is a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury. This protein also binds to clotting factor VIII (FVIII) in the circulation and stabilizes it.
Symptoms of Von Willebrand Disease include prolonged bleeding from skin lacerations, bleeding from nose and gums, and menorrhagia.
Different types of therapeutics have been utilized in the treatment of von Willebrand Disease, including desmopressin, clot-stabilizing medications, replacement therapies, contraceptives, and others. Desmopressin is extensively used in the treatment of von Willebrand disease.

Market Analysis and Insights: Global Von Willebrand Disease (VWD) Therapeutics Market
The global Von Willebrand Disease (VWD) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Von Willebrand Disease (VWD) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Von Willebrand Disease (VWD) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Von Willebrand Disease (VWD) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Von Willebrand Disease (VWD) Therapeutics market.

Global Von Willebrand Disease (VWD) Therapeutics Scope and Segment
Von Willebrand Disease (VWD) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Von Willebrand Disease (VWD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Distribution Channel in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into
Desmopressin
Clot-Stabilizing Medication
Fibrinolytic Inhibitors
Replacement Therapy
Others

Market segment by Distribution Channel, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Based on regional and country-level analysis, the Von Willebrand Disease (VWD) Therapeutics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE

In the competitive analysis section of the report, leading as well as prominent players of the global Von Willebrand Disease (VWD) Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Apollo Therapeutics
Apotex
Bayer
Bio Products Laboratory
CSL
Ferring Pharmaceuticals
Glenmark Pharmaceuticals
Grifols

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Market Analysis by Type
1.3.1 Global Von Willebrand Disease (VWD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.3.2 Desmopressin
1.3.3 Clot-Stabilizing Medication
1.3.4 Fibrinolytic Inhibitors
1.3.5 Replacement Therapy
1.3.6 Others
1.4 Market by Application
1.4.1 Global Von Willebrand Disease (VWD) Therapeutics Market Share by Distribution Channel: 2020 VS 2026
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Pharmacies
1.5 Study Objectives
1.6 Years Considered

2 Global Growth Trends
2.1 Global Von Willebrand Disease (VWD) Therapeutics Market Perspective (2015-2026)
2.2 Von Willebrand Disease (VWD) Therapeutics Growth Trends by Regions
2.2.1 Von Willebrand Disease (VWD) Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Von Willebrand Disease (VWD) Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Von Willebrand Disease (VWD) Therapeutics Industry Dynamic
2.3.1 Von Willebrand Disease (VWD) Therapeutics Market Trends
2.3.2 Von Willebrand Disease (VWD) Therapeutics Market Drivers
2.3.3 Von Willebrand Disease (VWD) Therapeutics Market Challenges
2.3.4 Von Willebrand Disease (VWD) Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Von Willebrand Disease (VWD) Therapeutics Players by Market Size
3.1.1 Global Top Von Willebrand Disease (VWD) Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Von Willebrand Disease (VWD) Therapeutics Revenue Market Share by Players (2015-2020)
3.2 Global Von Willebrand Disease (VWD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Von Willebrand Disease (VWD) Therapeutics Revenue
3.4 Global Von Willebrand Disease (VWD) Therapeutics Market Concentration Ratio
3.4.1 Global Von Willebrand Disease (VWD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Von Willebrand Disease (VWD) Therapeutics Revenue in 2019
3.5 Key Players Von Willebrand Disease (VWD) Therapeutics Area Served
3.6 Key Players Von Willebrand Disease (VWD) Therapeutics Product Solution and Service
3.7 Date of Enter into Von Willebrand Disease (VWD) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Von Willebrand Disease (VWD) Therapeutics Breakdown Data by Type
4.1 Global Von Willebrand Disease (VWD) Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Type (2021-2026)

5 Von Willebrand Disease (VWD) Therapeutics Breakdown Data by Distribution Channel
5.1 Global Von Willebrand Disease (VWD) Therapeutics Historic Market Size by Distribution Channel (2015-2020)
5.2 Global Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Distribution Channel (2021-2026)

6 North America
6.1 North America Von Willebrand Disease (VWD) Therapeutics Market Size (2015-2026)
6.2 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020)
6.3 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020)
6.4 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada

7 Europe
7.1 Europe Von Willebrand Disease (VWD) Therapeutics Market Size (2015-2026)
7.2 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020)
7.3 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020)
7.4 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size (2015-2026)
8.2 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020)
8.3 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020)
8.4 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia

9 Latin America
9.1 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size (2015-2026)
9.2 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020)
9.3 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020)
9.4 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size (2015-2026)
10.2 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020)
10.3 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2015-2020)
10.4 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE

11Key Players Profiles
11.1 Apollo Therapeutics
11.1.1 Apollo Therapeutics Company Details
11.1.2 Apollo Therapeutics Business Overview
11.1.3 Apollo Therapeutics Von Willebrand Disease (VWD) Therapeutics Introduction
11.1.4 Apollo Therapeutics Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020))
11.1.5 Apollo Therapeutics Recent Development
11.2 Apotex
11.2.1 Apotex Company Details
11.2.2 Apotex Business Overview
11.2.3 Apotex Von Willebrand Disease (VWD) Therapeutics Introduction
11.2.4 Apotex Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.2.5 Apotex Recent Development
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer Von Willebrand Disease (VWD) Therapeutics Introduction
11.3.4 Bayer Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.3.5 Bayer Recent Development
11.4 Bio Products Laboratory
11.4.1 Bio Products Laboratory Company Details
11.4.2 Bio Products Laboratory Business Overview
11.4.3 Bio Products Laboratory Von Willebrand Disease (VWD) Therapeutics Introduction
11.4.4 Bio Products Laboratory Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.4.5 Bio Products Laboratory Recent Development
11.5 CSL
11.5.1 CSL Company Details
11.5.2 CSL Business Overview
11.5.3 CSL Von Willebrand Disease (VWD) Therapeutics Introduction
11.5.4 CSL Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.5.5 CSL Recent Development
11.6 Ferring Pharmaceuticals
11.6.1 Ferring Pharmaceuticals Company Details
11.6.2 Ferring Pharmaceuticals Business Overview
11.6.3 Ferring Pharmaceuticals Von Willebrand Disease (VWD) Therapeutics Introduction
11.6.4 Ferring Pharmaceuticals Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.6.5 Ferring Pharmaceuticals Recent Development
11.7 Glenmark Pharmaceuticals
11.7.1 Glenmark Pharmaceuticals Company Details
11.7.2 Glenmark Pharmaceuticals Business Overview
11.7.3 Glenmark Pharmaceuticals Von Willebrand Disease (VWD) Therapeutics Introduction
11.7.4 Glenmark Pharmaceuticals Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.7.5 Glenmark Pharmaceuticals Recent Development
11.8 Grifols
11.8.1 Grifols Company Details
11.8.2 Grifols Business Overview
11.8.3 Grifols Von Willebrand Disease (VWD) Therapeutics Introduction
11.8.4 Grifols Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.8.5 Grifols Recent Development
11.9 Octapharma
11.9.1 Octapharma Company Details
11.9.2 Octapharma Business Overview
11.9.3 Octapharma Von Willebrand Disease (VWD) Therapeutics Introduction
11.9.4 Octapharma Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.9.5 Octapharma Recent Development
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Von Willebrand Disease (VWD) Therapeutics Introduction
11.10.4 Takeda Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.10.5 Takeda Recent Development

12Analyst’s Viewpoints/Conclusions

13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

...

【掲載企業】

Apollo Therapeutics、Apotex、Bayer、Bio Products Laboratory、CSL、Ferring Pharmaceuticals、Glenmark Pharmaceuticals、Grifols、Octapharma、Takeda

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のフォンウィルブランド病(VWD)治療薬市場2026:インサイト・予測(Global Von Willebrand Disease (VWD) Therapeutics Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。